StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research note issued to investors on Friday. The brokerage issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of Brooklyn ImmunoTherapeutics stock opened at $0.21 on Friday. The firm has a 50-day moving average of $1.63 and a 200-day moving average of $1.92. The stock has a market cap of $12.07 million, a PE ratio of -0.51 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52-week low of $0.17 and a 52-week high of $10.10.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.